Share on StockTwits

Alexion Pharmaceuticals (NASDAQ:ALXN) CEO Leonard Bell unloaded 90,280 shares of the company’s stock on the open market in a transaction dated Friday, June 20th. The stock was sold at an average price of $163.60, for a total value of $14,769,808.00. Following the transaction, the chief executive officer now directly owns 1,032,331 shares of the company’s stock, valued at approximately $168,889,352. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

A number of analysts have recently weighed in on ALXN shares. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Alexion Pharmaceuticals in a research note on Friday, May 9th. They now have a $210.00 price target on the stock, up previously from $200.00. Separately, analysts at Zacks reiterated an “outperform” rating on shares of Alexion Pharmaceuticals in a research note on Friday, April 25th. They now have a $187.00 price target on the stock. Finally, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Friday, April 25th. They now have a $220.00 price target on the stock, up previously from $219.00. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Alexion Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $182.31.

Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 2.30% during mid-day trading on Monday, hitting $161.66. 968,419 shares of the company’s stock traded hands. Alexion Pharmaceuticals has a 52 week low of $87.01 and a 52 week high of $185.43. The stock’s 50-day moving average is $162.3 and its 200-day moving average is $154.3. The company has a market cap of $31.976 billion and a P/E ratio of 100.04.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, April 24th. The company reported $1.53 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.26 by $0.27. The company had revenue of $566.60 million for the quarter, compared to the consensus estimate of $560.22 million. During the same quarter in the prior year, the company posted $0.65 earnings per share. The company’s quarterly revenue was up 67.2% on a year-over-year basis. On average, analysts predict that Alexion Pharmaceuticals will post $4.87 earnings per share for the current fiscal year.

Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.